InfaCare Pharmaceutical Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Employees
-
10
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$425M
InfaCare Pharmaceutical General Information
Description
Developer of a pharmaceutical drug intended for the treatment of neonatal and pediatric diseases. The company's pharmaceutical drug includes heme oxygenase inhibitor which is injected via a single, intramuscular injection in the body of term and pre-term newborns facing neonatal HB, breaks down heme and inhibits the body's production of bilirubin for a period of days, enabling clinicians to reduce the need for phototherapy and exchange transfusions.
Contact Information
Website
www.infacare.comCorporate Office
- 8 Neshaminy Interplex Drive
- Suite 221
- Trevose, PA 19053
- United States
Corporate Office
- 8 Neshaminy Interplex Drive
- Suite 221
- Trevose, PA 19053
- United States
InfaCare Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 25-Sep-2017 | $425M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 07-Jun-2017 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series C) | 08-Jul-2015 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series C) | 20-Mar-2013 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series B) | 27-Oct-2008 | Completed | Startup | |||
| 4. Early Stage VC (Series A) | 10-Mar-2006 | Completed | Startup | |||
| 3. Angel (individual) | 29-Dec-2003 | Completed | Startup | |||
| 2. Angel (individual) | 16-Jun-2003 | $786K | $861K | Completed | Startup | |
| 1. Angel (individual) | 06-May-2002 | $75K | $75K | Completed | Startup |
InfaCare Pharmaceutical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Junior Preferred |
InfaCare Pharmaceutical Comparisons
Industry
Financing
Details
InfaCare Pharmaceutical Competitors (29)
One of InfaCare Pharmaceutical’s 29 competitors is XyloCor Therapeutics, a Venture Capital-Backed company based in King of Prussia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| XyloCor Therapeutics | Venture Capital-Backed | King of Prussia, PA | ||||
| Neurelis | Venture Capital-Backed | San Diego, CA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Pacira BioSciences | Formerly VC-backed | Tampa, FL | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA |
InfaCare Pharmaceutical Patents
InfaCare Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017263628-A1 | Methods for treating hyperbilirubinemia with stannsoporfin and phototherapy | Inactive | 12-May-2016 | ||
| WO-2017197249-A3 | Methods for treating hyperbilirubinemia with stannsoporfin and phototherapy | Inactive | 12-May-2016 | ||
| WO-2017197249-A2 | Methods for treating hyperbilirubinemia with stannsoporfin and phototherapycross-reference to related applications | Inactive | 12-May-2016 | ||
| JP-2019052176-A | Drug for treatment of infant hyperbilirubinemia or symptoms thereof containing stannsoporfin | Pending | 01-Dec-2011 | ||
| JP-2018012717-A | Drugs comprising stannsoporfin for treating hyperbilirubinemia | Pending | 01-Dec-2011 | A61K31/555 |
InfaCare Pharmaceutical Signals
InfaCare Pharmaceutical Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| HealthCare Ventures | Venture Capital | Minority | ||
| Longitude Capital | Venture Capital | Minority | ||
| Lookout Capital | Venture Capital | Minority | ||
| Pequot Ventures | Venture Capital | Minority |
InfaCare Pharmaceutical FAQs
-
When was InfaCare Pharmaceutical founded?
InfaCare Pharmaceutical was founded in 2001.
-
Where is InfaCare Pharmaceutical headquartered?
InfaCare Pharmaceutical is headquartered in Trevose, PA.
-
What is the size of InfaCare Pharmaceutical?
InfaCare Pharmaceutical has 10 total employees.
-
What industry is InfaCare Pharmaceutical in?
InfaCare Pharmaceutical’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is InfaCare Pharmaceutical a private or public company?
InfaCare Pharmaceutical is a Private company.
-
What is the current valuation of InfaCare Pharmaceutical?
The current valuation of InfaCare Pharmaceutical is .
-
What is InfaCare Pharmaceutical’s current revenue?
The current revenue for InfaCare Pharmaceutical is .
-
How much funding has InfaCare Pharmaceutical raised over time?
InfaCare Pharmaceutical has raised $84.1M.
-
Who are InfaCare Pharmaceutical’s investors?
Atlas Venture, HealthCare Ventures, Longitude Capital, Lookout Capital, and Pequot Ventures have invested in InfaCare Pharmaceutical.
-
Who are InfaCare Pharmaceutical’s competitors?
XyloCor Therapeutics, Neurelis, Voyager Therapeutics, Pacira BioSciences, and Vertex Pharmaceuticals are some of the 29 competitors of InfaCare Pharmaceutical.
-
When was InfaCare Pharmaceutical acquired?
InfaCare Pharmaceutical was acquired on 25-Sep-2017.
-
Who acquired InfaCare Pharmaceutical?
InfaCare Pharmaceutical was acquired by Mallinckrodt Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process